Here are the DEF 14A proxy statements from Wave Life Sciences Ltd. (WVE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow WVE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WVE filings page.
Wave Life Sciences, Inc. asks stockholders to vote at its November 12, 2026 annual meeting on four proposals: elect nine directors, ratify KPMG LLP as auditor for fiscal 2026, approve an amendment increasing shares available under the 2021 Equity Incentive Plan, and cast a non-binding advisory vote on named executive officer compensation. The board recommends approval of each proposal.
The meeting was postponed from its historical August schedule following the completed redomiciliation on August 7, 2026, which made Wave Life Sciences, Inc. the ultimate parent and Wave Life Sciences Ltd. its indirect wholly owned subsidiary. The record date was October 8, 2026, when 197,228,058 common shares were issued and outstanding. At the 2025 annual meeting, over 99% of votes cast supported the advisory compensation proposal; the compensation committee said no significant program changes were necessary at that time.
Wave Life Sciences Ltd. is asking shareholders to approve a redomiciliation that will make newly formed Wave Life Sciences, Inc., a Delaware corporation, the parent of the group. Each Wave-Singapore ordinary share will be exchanged on a one-for-one basis for Wave-Delaware common stock, which is expected to continue trading on Nasdaq under the symbol “WVE.”
The company cites closer alignment with its largely U.S.-based operations and shareholder base, as well as reduced duplicate regulatory, legal and reporting costs, as key reasons. A Singapore court–sanctioned Scheme of Arrangement requires approval by a majority in number of voting shareholders and at least 75% of shares voted at a June 22, 2026 special meeting in Cambridge, Massachusetts. Shareholders will not have appraisal rights under Singapore law, and the company intends that most holders will not recognize gain or loss for U.S. federal income tax purposes, though complex U.S., Singapore and U.K. tax consequences and potential changes in effective tax rate are highlighted as risks.